文献速递系统性红斑狼疮

系统性红斑狼疮相关精神病的40年专科中心经验

Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究回顾性分析709例SLE患者,其中18例(2.5%)在平均17.5年随访中发生狼疮精神病。66.7%的患者经抗精神病药联合免疫抑制治疗后完全缓解,未发现显著生物标志物,但抗RNP抗体和GABABR抗体的初步关联值得进一步探索。

要点

  • 狼疮精神病罕见(2.5%),但经抗精神病药联合免疫抑制治疗多数可完全缓解。
  • 抗RNP抗体在狼疮精神病患者中更常见(50.0% vs 26.5%),但差异未达显著。
  • GABABR抗体在固定细胞检测中比例较高(30.0% vs 11.1%),但活细胞检测未重复。

核心结论

  • 狼疮精神病虽然罕见但可治疗,本队列中66.7%的患者完全缓解。
  • 未发现显著生物标志物,但抗RNP抗体和GABABR抗体的初步关联需更大样本验证。

研究设计与样本

  • 回顾性队列研究,纳入1978年1月至2018年11月专科中心709例SLE患者。
  • 比较精神病组与非精神病组的临床、生化和免疫学特征,并用新型细胞法检测血清神经元表面抗体。

主要发现

  • 18/709(2.5%)患者发生狼疮精神病,平均随访17.5±11.0年。
  • 精神病完全缓解率66.7%(12/18),治疗包括抗精神病药(38.9%)和免疫抑制(甲泼尼龙72.2%、环磷酰胺55.6%、利妥昔单抗16.7%、血浆置换27.8%、泼尼松50%)。
  • 抗RNP抗体在精神病组为50.0% vs 26.5%,抗心磷脂抗体为5.6% vs 30.0%,差异均未显著。
  • 固定细胞法检测GABABR抗体:精神病组3/10(30.0%)vs 年龄性别匹配对照3/27(11.1%),P=0.114;活细胞法未重复。
  • NMDAR抗体在所有样本中均未检出。

临床怎么用

  • 对SLE患者出现精神病症状应警惕狼疮精神病,及时联合抗精神病药与免疫抑制治疗。
  • 抗RNP抗体阳性或抗心磷脂抗体阴性可能提示风险,但证据尚不充分。
  • GABABR抗体检测结果需谨慎解读,固定细胞法阳性需活细胞法确认。

局限性

  • 样本量小(仅18例精神病患者),统计效力有限。
  • 回顾性设计,可能存在信息偏倚。
  • GABABR抗体结果未在活细胞检测中重复,生物标志物关联不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The long-term outcome of psychosis in association with systemic lupus erythematosus (SLE) has been insufficiently characterised. We used a specialist centre cohort of patients with SLE and psychosis to investigate their clinical outcome and phenotypic and laboratory characteristics. METHODS: Retrospective cohort study of 709 SLE patients seen at a specialist centre between January 1978 and November 2018. Clinical, biochemical and immunological characteristics (Bonferroni corrected), and serum neuronal surface antibody profile using novel cell-based assays, were compared between patients with and without psychosis. RESULTS: Eighteen (18/709, 2.5%) patients developed lupus psychosis over a mean ± SD of 17.5 ± 11.0 years follow-up. Psychosis fully remitted in 66.7% (12/18) with a combination of antipsychotic (in 38.9%) and immunosuppressive therapy (methylprednisolone 72.2%, cyclophosphamide 55.6%, rituximab 16.7%, plasma exchange 27.8%, prednisolone 50%). Patients who developed lupus psychosis may be more likely to have anti-RNP antibodies (50.0% vs 26.5%) and less likely to have anti-cardiolipin antibodies (5.6% vs 30.0%), but this was not significant in our small sample. Neuronal surface autoantibody tests found GABABR autoantibodies in 3/10 (30.0%) lupus psychosis patients compared with only 3/27 (11.1%) in age- and sex-matched SLE controls using fixed cell-based assays (P =0.114). However, GABABR antibodies were not replicated using a live cell-based assay. NMDAR-antibodies were not detected with fixed or live cell assays in any samples. CONCLUSION: Lupus psychosis is rare but treatable. In this rare sample of eighteen patients from a 40-year cohort, no significant biomarker was found, but some preliminary associations warrant further exploration in a larger multicentre analysis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Abrol E, Coutinho E, Chou M, et al. Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre. Rheumatology (Oxford). 2021. PMID: 33629101. doi:10.1093/rheumatology/keab160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。